Breaking News

Tweet TWEET

Progenics Pharmaceuticals to Webcast Investor and Analyst Day July 18, 2013

Progenics Pharmaceuticals to Webcast Investor and Analyst Day July 18, 2013

TARRYTOWN, N.Y., July 16, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) will webcast its upcoming investor and analyst day, taking
place July 18, 2013 from 2:30pm – 5:30pm ET. Guest speakers Jonathan Simons,
M.D., president & chief executive officer of the Prostate Cancer Foundation,
and John Babich, Ph.D., co-founder and former CEO of Progenics' Molecular
Insight subsidiary, will join Progenics executives in providing an update on
commercial and pipeline products and candidates, business development and
corporate outlook.

The live webcast will be available in the Events section of the Progenics
website, www.progenics.com/events.cfm. To ensure a timely connection, users
should register at least 15 minutes prior to the scheduled start. An archive
of the event will be available for 90 days.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development.Progenics' first-in-class PSMA targeted
technology platform includes an antibody drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase 2 clinical trials. Among
other assets in its pipeline of targeted radiotherapy and molecular imaging
compounds is Azedra™, an ultra-orphan radiotherapy candidate also in phase 2
under an SPA.Progenics' first commercial product, Relistor^®
(methylnaltrexone bromide) for opioid-induced constipation, is partnered with
and marketed by Salix Pharmaceuticals, Inc.Ono Pharmaceutical Co. is
developing Relistor in Japan. For additional information, please visit
www.progenics.com.

This release may contain projections and other forward-looking statements
regarding future events. Such statements are predictions only, and are subject
to risks and uncertainties that could cause actual events or results to differ
materially. These risks and uncertainties include, among others, the cost,
timing and results of clinical trials and other development activities; the
unpredictability of the duration and results of regulatory review of New Drug
Applications and Investigational NDAs; market acceptance for approved
products; generic and other competition; the possible impairment of, inability
to obtain and costs of obtaining intellectual property rights; and possible
safety or efficacy concerns, general business, financial and accounting
matters, litigation and other risks. More information concerning Progenics and
such risks and uncertainties is available on its website, and in its press
releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this release as of its
date and does not undertake any obligation to update or revise it, whether as
a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
this release.

CONTACT: Progenics Pharmaceuticals, Inc.:
         Kathleen Fredriksen
         Director, Corporate Development
         (914) 789-2871
         kfredriksen@progenics.com

company logo